INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
This study is currently recruiting participants.
Verified May 2013 by Pfizer
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01367457
First received: June 3, 2011
Last updated: May 6, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
| Condition | Intervention |
|---|---|
|
Carcinoma, Renal Cell Lymphoma, Mantle-Cell |
Other: Temsirolimus (Non-Interventional Study) |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Retrospective |
| Official Title: | INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 100 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Patients that received treatment with Temsirolimus
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
|
Other: Temsirolimus (Non-Interventional Study)
There is not any intervention in this study.
|
Detailed Description:
There is not sampling method
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Criteria
Inclusion Criteria:
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Exclusion Criteria:
Patients that do not have a minimum (pre-specified) of data in their clinical record.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01367457
Contacts
| Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
Locations
| Spain | |
| Hospital Universitario Central de Asturias | Recruiting |
| Oviedo, Asturias, Spain, 33006 | |
| Hospital de Cabue�S | Recruiting |
| Cabuens, Gijon, Spain, 33394 | |
| Complejo Hospitalario Materno-Infantil Insular de Las Palmas | Recruiting |
| Las Palmas de Gran Canaria, Las Palmas, Spain, 35016 | |
| Hospital de Navarra | Recruiting |
| Pamplona, Navarra, Spain, 31008 | |
| Hospital Provincial de Castellon | Recruiting |
| Castellon, Valencia, Spain, 12002 | |
| Complexo Hospitalario Universitario A Coru� | Recruiting |
| A Coruna, Spain, 15006 | |
| Complejo AAsistencial de Avilla | Recruiting |
| Avila, Spain, 05004 | |
| Hospital del Mar | Recruiting |
| Barcelona, Spain, 8940 | |
| Hospital de La Santa Creu I Sant Pau | Recruiting |
| Barcelona, Spain, 08025 | |
| Hospital Vall D�Hebron | Recruiting |
| Barcelona, Spain, 08035 | |
| Complexo Hospitalario Universitario A Coru�. Hospital Teresa Herrera | Recruiting |
| La Coruna, Spain, 15006 | |
| MD Anderson Cancer Center | Recruiting |
| Madrid, Spain, 28033 | |
| Hospital General Universitario Gregorio Mara�N | Recruiting |
| Madrid, Spain, 28007 | |
| Hospital de Madrid Norte - Sanchinarro | Recruiting |
| Madrid, Spain, 28050 | |
| Hospital Universitario La Paz | Recruiting |
| Madrid, Spain, 28046 | |
| Hospital Clinico Universitario | Recruiting |
| Santiago de Compostela, Spain, 15706 | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT01367457 History of Changes |
| Other Study ID Numbers: | B1771017, INHIBITOR |
| Study First Received: | June 3, 2011 |
| Last Updated: | May 6, 2013 |
| Health Authority: | Spain: Comité Ético de Investigación Clínica |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Renal Cell Lymphoma Lymphoma, Mantle-Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Sirolimus Everolimus Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antifungal Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 23, 2013